Eckert & Ziegler awards grants to young researchers in nuclear medicine
Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Miscellaneous
19.10.2011 / 13:37
---------------------------------------------------------------------
Berlin, October 19, 2011. This year's travel grants from Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) have been awarded to five nuclear medicine scientists from Australia, Germany, the Netherlands and Switzerland. The prize-winners were selected by a jury from the European Association of Nuclear Medicine (EANM) from a total of 482 entries. Work in the fields of oncologic, cardiovascular and pulmonary diagnostic as well as in the field of oncologic therapy received recognition. The travel grants, which amount to 1,000 EUR each, were presented today at the annual congress of the EANM in Birmingham to:
T. Heusner, Germany: Diagnostic accuracy of virtual 3D FDG-PET/CT bronchoscopy for the detection of lymph node metastases in non small cell lung cancer patients
M. Hofmann, Australia: Gallium-68 PET/CT Ventilation Perfusion Imaging for Acute Pulmonary Embolism
C. Kobe, Germany: Assessment of residual bulky tumor using FDG-PET in patients with advanced stages after completion of chemotherapy. Final report of the GHSG
HD15 trial
J. Schaap, Netherlands: Coronary calcium scoring does not add to myocardial perfusion SPECT in the exclusion of coronary artery disease in high risk patients
M. Walter, Switzerland: [90Yttrium-DOTA]-TOC vs. [90Yttrium-DOTA]-TOC plus [177Lutetium-DOTA]-TOC in Metastasized Neuroendocrine Cancers
'The nuclear imaging highly contributes to the early diagnosis of cancer and neurological diseases such as Alzheimer's. A huge number of biological markers helping to make the process of a disease visible are at present in the state of development. The future belongs to the imaging biomarkers', explained Dr. Andreas Eckert, CEO of Eckert & Ziegler.
In presenting the 'EANM Eckert & Ziegler Abstract Award' Eckert & Ziegler wishes to encourage young researchers to present their results to a wider audience.
Eckert & Ziegler AG is one of the world's largest providers of isotope component technology for radiation therapy and nuclear medicine. The Berlin based company has 570 employees and is listed at the Frankfurt stock exchange.
You can find further information about the Eckert & Ziegler travel grant at http://www.ezag.com/home/about-us/social-engagement/abstract-award.html
Your contact:
Eckert & Ziegler AG
Karolin Riehle, Investor Relations & PR
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 941084-138, Fax-112
E-mail: karolin.riehle@ezag.de, www.ezag.com
End of Corporate News
---------------------------------------------------------------------
19.10.2011 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English Company: Eckert & Ziegler Strahlen- und Medizintechnik AG Robert-Rössle-Str.10 13125 Berlin Germany Phone: 49 30 941084-138 Fax: 49 30 941084-112 E-mail: karolin.riehle@ezag.de Internet: www.ezag.de ISIN: DE0005659700 WKN: 565970 Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart; Freiverkehr in Berlin, Düsseldorf, Hamburg, München
End of News DGAP News-Service
--------------------------------------------------------------------- 142767 19.10.2011